How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse […]
Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »
Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made
J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell
24 cell therapy & stem cell stocks I’m following Read More »
This is a post by Mina Kim, a UC Davis student intern for The Niche blog, about the main types of cellular therapies being studied clinically for COVID-19. During the novel coronavirus pandemic with millions of COVID-19 cases, the development of safe and effective treatments for patients is vital. Cellular medicine treatments are one of
Review of 4 cell therapy types under study for COVID-19 Read More »
My weekly roundups of biomedical news tend to focus on stem cells, but I read more broadly so it’s not just stem cells but also CAR-T cells and a lot more this week. CAR-T cells as senolytics? A team led by Scott Lowe has a new intriguing paper in Nature on using CAR-T cells to
Weekly roundup: CAR-T cells, exosomes, trout cloning Read More »
The idea of testing stem cells for COVID-19 may be music to the ears of some folks as an opportunity, but to me from the beginning it sounded mostly like a spaghetti on the wall road to trouble. There is buzz out there that some kind of stem cells or other cells will help with
Field throws stem cells for COVID-19 like spaghetti on the wall Read More »
It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an
COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »
This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm
FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »
Today’s post includes a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. Sometimes people call these “r mat” with a space. As of December 12, 2023 there are 85 RMATs in the public domain. I also include FDA data on RMAT submissions via an FDA RMAT resource
Updated FDA granted RMAT List (85) Read More »